A Case Report of Immunotherapy-Resistant MSI-H Gastric Cancer with Significant Intrapatient Tumoral Heterogeneity Characterized by Histologic Dedifferentiation

Nikhila Kethireddy 1, Leonidas Arvanitis 2*, Janine LoBello 3, Yanghee Woo 4, Szabolcs Szelinger 3 and Joseph Chao 5, *

1 Department of Hematology/Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA; nkethireddy@dhs.lacounty.gov
2 Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; larvanitis@coh.org
3 Exact Sciences, Phoenix, AZ 85004, USA; jlobello@exactsciences.com (J.L.); sszelinger@exactsciences.com (S.S.)
4 Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; yhwoo@coh.org
5 Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA

* Correspondence: jchao@coh.org; Tel.: +1-626-218-3494; Fax: +1-626-218-8233

Abstract: We describe a patient with both gastric adenocarcinoma and metastatic squamous cell carcinoma (SCC) of unknown primary site. The possibility of a single malignant clonal process as opposed to differing primaries was supported by the finding of both histologies exhibiting high microsatellite instability. Despite evidence of tumor microsatellite instability, the patient’s disease process did not respond to immune checkpoint inhibition. Our pursuit of whole-exome sequencing and comparing the single-nucleotide variant profiles of both tumors supported a single clonal process with the development of significant intratumoral heterogeneity. High intratumoral heterogeneity has posed a challenge to precision medicine approaches, but we also provide a review of the literature of this phenomenon mediating resistance to immunotherapy strategies.

Keywords: immunotherapy; microsatellite instability; intratumoral heterogeneity; whole-exome sequencing

1. Introduction

Gastric cancer (GC) accounts for over 1 million new cases and an estimated 769,000 deaths every year [1]. Distinguishing metastatic recurrence and the development of a second primary carries prognostic and therapeutic implications [2]. Conventionally, the histopathological comparison of tissue specimens has been utilized. However, this has limitations, including interobserver variability, tumor heterogeneity, and changes in the tumor microenvironment that can impact diagnosis [2]. The use of comprehensive genomic profiling (CGP) can augment histopathologic analysis while concurrently pinpointing genomic alterations that have therapeutic potential [2–6]. Clinical trials for targeted therapies in individuals with metastatic GC who were positive for ERBB2, MET, EGFR, and FGFR2 showed variable results [7–14]. One potential reason these trials did not show a significant benefit is that the primary tumor was used to guide treatment [7].

We describe a patient with both gastric adenocarcinoma and squamous cell carcinoma (SCC) of unknown primary site. We postulate that despite different histopathological diagnoses our patient likely had a single metastatic disease process rather than two separate primaries. Our conclusion is supported by comparisons of the single-nucleotide variant (SNV) profiles derived from whole-exome sequencing between the primary and metastatic sites aligning with a single clonal process, demonstrating interlesional heterogeneity. We
believe that dedifferentiation from GC to SCC is reflective of substantial intratumoral heterogeneity (ITH) in our patient, which likely led to immune checkpoint inhibitor (ICI) resistance. Written informed consent was obtained from the patient for the collection, analysis, and publication of deidentified molecular and clinical data under an institutional-review-board-approved research protocol.

2. Case Report

A 56-year-old Asian female with no past medical history self-palpated a left neck lump. She was briefly residing outside the US and while there was sent for positron emission tomography/computerized tomography (PET/CT), which demonstrated enlarged lymph nodes in the neck, mediastinum, axilla, left gastric region, common hepatic, and retroperitoneum. The scan also revealed irregular wall thickening of the gastric lower body with extramural infiltration. The patient underwent a core biopsy of the left level IV neck lymph node (LN), which showed poorly differentiated carcinoma, favoring metastatic SCC. She had bilateral screening mammograms and breast ultrasounds, which were both unremarkable. Esophagogastroduodenoscopy (EGD) identified an ulcerating infiltrative lesion in the midbody of the stomach. The pathology revealed moderate to poorly differentiated adenocarcinoma. A colonoscopy found benign polyps.

She returned to the United States and presented to our institution. Her physical exam was significant for mild epigastric tenderness. The lab work, including complete blood counts, carcinoembryonic antigen, CA 125, CA 15-3, and alpha fetoprotein, was normal. A CT of the abdomen and pelvis demonstrated a mass-like gastric wall thickening, extensive conglomerated lymphadenopathy in the upper abdomen, and peritoneal carcinomatosis with small volume malignant ascites. She was evaluated with a cervical exam and Pap smear, which were normal, ruling out a cervical SCC as a primary origin of the metastatic SCC. Her initial biopsy samples were unobtainable from overseas. A repeat biopsy of a different axillary enlarged LN was pursued. An EGD for biomarker analyses was performed prior to starting any therapy and confirmed a necrotic mass in the body of the stomach. The pathology was consistent with moderately differentiated adenocarcinoma with mucinous features. Biomarker analyses, including programmed death-ligand 1 (PD-L1) expression, showed a combined positive score (CPS) of 0. The HER2/neu immunohistochemistry (IHC) was negative. She had a loss of the nuclear expression of DNA mismatch repair (MMR) protein PMS2 with a partial loss of MLH1 and retained the nuclear expression of MSH2 and MSH6. The biopsy of the axillary LN demonstrated a metastatic SCC. The PD-L1 tumor proportion score (TPS) was 5%, the PD-L1 combined positive score (CPS) was also 5, and the MMR IHC showed a loss of PMS2 and retained nuclear expression of MLH1, MLH2, and MSH6. Both the axillary LN and gastric mass showed a loss of MMR protein PMS2, demonstrating that both tumors had microsatellite instability (MSI-H/dMMR). With the apparent separate tumor histologies all being MSI-H, germline testing for Lynch syndrome was conducted, with no germline pathogenic mutations being detected in MLH1, MSH2, MSH6, PMS2, or EPCAM.

FOLFOX and pembrolizumab were initiated, given that the tumors were MSI-H. Whole-exome sequencing of both the adenocarcinoma and the SCC using the Oncomap™ ExTra test confirmed the MSI-H status and numerous somatic alterations (Table 1). The Oncomap™ ExTra assay (formerly known as GEM ExTra) detects single-nucleotide variants, indels, and focal copy number alterations with a mean target coverage of 400× for tumor DNA with 98.8% analytic sensitivity [15]. Despite receiving close to 6 weeks of chemoimmunotherapy, she remained with poor oral intake and was taken for a surgical j-tube placement and diagnostic laparoscopy. A peritoneal biopsy showed metastatic SCC with a PD-L1 CPS of 5 and MMR IHC with absent PMS2. She resumed treatment but developed bleeding from her primary tumor. A palliative resection was attempted but aborted due to the extensive involvement of the vasculature by the primary tumor. A biopsy of the lesser and greater curvature lymph nodes was conducted intraoperatively for further biomarker testing, given the lack of response despite 3 months of therapy by this point.
Four nodes from the greater curvature were positive for metastatic carcinoma, one of which consisted of both mucinous adenocarcinoma and SCC morphology within the same LN (Figure 1). The MMR IHC on these samples showed a loss of nuclear expression for PMS2, and PD-L1 testing revealed a CPS of 1. Unfortunately, despite palliative radiotherapy and 2nd-line treatment, her disease continued to progress, and she was referred to hospice and passed away 1 month later.

Table 1. Actionable and additional alterations of interest detected by Oncomap™ ExTra (Exact Sciences) in the five specimens received for somatic profiling.

| Tumor Histology | Adenocarcinoma | SCC | SCC | SCC | Adenocarcinoma |
|-----------------|----------------|-----|-----|-----|----------------|
| Tissue Source   | Stomach        | Right Axilla Lymph Node | Peritoneal biopsy | Greater Curvature Lymph Node | Greater Curvature Lymph Node |
| Timing of Tumor collection relative to start of therapy | 15 days prior | 11 days prior | 41 days post | 86 days post | 86 days post |

Alterations associated with FDA on/off label therapies

| Alteration               | Adenocarcinoma | SCC | SCC | SCC | Adenocarcinoma |
|--------------------------|----------------|-----|-----|-----|----------------|
| ATM:p.R2034*             | 0.15           |     |     |     |                |
| FBXW7:p.E78*             | 0.17           | 0.26| 0.12| 0.07|                |
| MSI-High                 | Yes            | Yes | Yes | Yes | Yes            |
| PMS2:p.E109fs            | 0.15           |     |     |     |                |
| POLD1:p.D1013fs          |                | 0.28|     |     |                |
| PTCH1:p.S1203fs          | 0.16           |     |     |     |                |
| TMB-High (≥20 mutations/Mb) | Yes         | Yes | Yes | No  | No             |

Alterations with clinical trial enrollment available

| Alteration               | Adenocarcinoma | SCC | SCC | SCC | Adenocarcinoma |
|--------------------------|----------------|-----|-----|-----|----------------|
| ARID1A:p.G240fs          | 0.14           |     |     |     |                |
| ARID1A:p.N1784fs         |                | 0.24| 0.15|     | 0.06           |
| ARID2:p.V681fs           | 0.20           | 0.37| 0.20| 0.10|                |
| ASXL1:p.G645fs           |                |     | 0.27|     |                |
| ATR:p.F1134fs            |                | 0.14|     |     |                |
| CHEK1:p.T226fs           |                | 0.17|     |     |                |
| ERCC5:p.K917fs           |                | 0.14|     |     |                |
| FANCM:p.V1336fs          |                | 0.22|     |     |                |
| GNAS:p.R844C             |                | 0.02|     |     | 0.03           |
| KRAS:p.G13D              |                | 0.38| 0.19| 0.10|                |
| MLH3:p.N674fs            |                | 0.23|     |     |                |
| MSH3:p.K383fs            |                | 0.24|     |     | 0.09           |
| RNF43:p.G659fs           | 0.17           | 0.27| 0.14|     |                |
| SLX4:p.P469fs            |                | 0.11|     |     |                |
| TMB-Intermediate (6–19 mutations/Mb) | No | No | No | Yes | No  |
| TP53:p.D281G             |                | 0.02|     |     |                |

Additional alterations of interest in each tumor type

| Alteration               | Adenocarcinoma | SCC | SCC | SCC | Adenocarcinoma |
|--------------------------|----------------|-----|-----|-----|----------------|
| ACVR2A:p.K437fs          | 0.28           |     |     |     | 0.12           |
| ARID1B:p.T71fs           |                | 0.05|     |     |                |
### Table 1. Cont.

| Tumor Histology | Adenocarcinoma | SCC | SCC | SCC | Adenocarcinoma |
|-----------------|----------------|-----|-----|-----|----------------|
| B2M:c.68-2A>G   | 0.12           |     |     | 0.05|                |
| B2M:p.L15fs     | 0.12           |     |     |     |                |
| B2M:p.V69fs     |                |     |     | 0.07|                |
| **CLDN18/ARHGAP26 Fusion** | Detected |     |     |     |                |
| CREBBP:p.I1084fs| 0.16           |     |     |     |                |
| JAK1:p.K860fs   | 0.26           |     |     |     |                |
| JAK1:p.P430fs   | 0.24           |     |     |     |                |
| KMT2B:p.Q575fs  | 0.16           | 0.26| 0.08| 0.05|                |
| KMT2C:p.K2797fs | 0.24           |     |     |     |                |
| KMT2C:p.N2842fs |                | 0.18| 0.19| 0.07|                |
| KMT2C:p.S2237*  | 0.20           | 0.23|     |     |                |
| KMT2D:p.A5076fs | 0.19           | 0.12|     |     |                |
| KMT2D:p.Q827fs  | 0.44           |     | 0.27| 0.14|                |
| SETDB1:p.P451fs | 0.20           |     |     |     |                |
| TET1:p.K23fs    | 0.23           |     | 0.15|     |                |

Table 1 Legend: Table 1 shows the Oncomap™ ExTra report of front-page somatic biomarkers that are either druggable, have clinical trial enrollment, or may be of interest due to prognostic or therapeutic relevance. Mutations are listed with p. annotation unless a splice event. For each sample, if a mutation was present the allelic fraction is listed in corresponding cell. For TMB and MSI, the presence or absence of TMB/MS status was noted as yes or no. Alterations that were present in both gastric and squamous cell carcinoma processes are shaded. No somatic VUS alterations listed.

---

**Figure 1.** Histologic examination of an excisional lymph node exhibiting contiguous areas of both adenocarcinoma and squamous cell carcinoma. (Left panel) representative H&E section. (Middle panel) the same section with p40 staining of the squamous cell carcinoma. (Right panel) the same section distinguishing areas of CDX2 staining of the adenocarcinoma.

### 3. Discussion

To our knowledge, there are few cases reported describing intratumor heterogeneity potentially mediating immunotherapy resistance. Our case describes a patient with both gastric adenocarcinoma and SCC of unknown primary site. We postulate that despite different histopathological diagnoses our patient likely had a single metastatic disease process rather than two separate primaries. During the disease course, we sampled the patient’s sites of disease at three timepoints (Figure 2): (1) gastric primary tumor and axillary lymph node, (2) post-treatment peritoneal metastasis, and (3) further post-treatment perigastric lymph nodes. A whole-exome analysis of all the samples shows similar mutations between the metastatic SCC and the primary gastric adenocarcinoma. The excisional LN with contiguous areas of both adenocarcinoma and SCC (Figure 1) was also supportive. For
instance, all the tissue samples demonstrated MSI-H as well as somatic mutations mutual to both the gastric adenocarcinoma and the SCC histology seen in the lymph nodes and peritoneal tissue biopsy (Table 1). We pursued more in-depth pairwise comparisons of the SNV profiles for all our samples to enable the testing of clonality or genetic independence between tumor samples (Table 2). The background mutation rate of a detected SNV in at least one of the samples was determined by analyzing the public TCGA pan-cancer database of over 11,000 individual patient samples comprising 66 differing tumor types. Our multiple pairwise test for clonality comparisons indicated that all five samples were significantly associated with a common clonal origin (Table 2). As expected, support for clonality was highest between samples with the same histology, but statistically significant support remained even between samples with differing histology and differing sampling timepoints.

Table 2. Pairwise clonality test of somatic alterations.

| Site1_Origin           | Site2_Origin       | n1 | n2 | Match | LRstat | maxKSI | LR (p-Value) |
|------------------------|--------------------|----|----|-------|--------|--------|--------------|
| Stomach_Gastric        | RightAxilla_SCC    | 858| 1021| 79    | 448    | 0.08   | <0.01        |
| Stomach_Gastric        | Peritoneal_SCC     | 858| 842 | 71    | 402    | 0.08   | <0.01        |
| Stomach_Gastric        | Lymph_SCC          | 858| 683 | 59    | 330    | 0.08   | <0.01        |
| Stomach_Gastric        | Lymph_Gastric      | 858| 171 | 146   | 1037   | 0.28   | <0.01        |
| Right Axilla_SCC       | Peritoneal_SCC     | 1021| 842 | 683   | 5900   | 0.73   | <0.01        |
| Right Axilla_SCC       | Lymph_SCC          | 1021| 683 | 567   | 4776   | 0.67   | <0.01        |
| Right Axilla_SCC       | Lymph_Gastric      | 1021| 171 | 12    | 51     | 0.02   | <0.01        |
| Peritoneal_SCC         | Lymph_SCC          | 842| 683 | 556   | 4794   | 0.73   | <0.01        |
| Peritoneal_SCC         | Lymph_Gastric      | 842| 171 | 13    | 59     | 0.03   | <0.01        |
| Lymph_Gastric          | Lymph_SCC          | 171| 683 | 11    | 50     | 0.03   | <0.01        |

Table 2 Legend: In Table 2, each row contains the result of a pairwise comparison of somatic SNV profiles utilizing the SNVtest module of the Clonality R package [16]. Comparisons are ordered by tumor collection dates. Dates are listed in Table 1. n1 = somatic alterations identified for site 1. n2 = somatic alterations identified in tumor site 2. Match = number of matching alterations between two sites. LRStat = likelihood ratio statistics. maxKSI = clonal strength between tumor sites. Note for interpretation: while there is high clonal relatedness between tumor sites with similar origin, especially between the squamous cell carcinomas, as indicated by maxKSI scores of >0.5, predictions suggest clonality between all tumor sites with possibly different backgrounds, as comparisons for clonality hypothesis are p < 0.01 across all pairwise comparisons.
Intrapatient ITH can be a determinant of immunotherapy resistance, which may have been the case in our patient [17]. We suggest that the primary manifestation of heterogeneity is the dedifferentiation of the primary tumor adenocarcinoma into a squamous cell histology in the metastatic sites. Furthermore, within the same perigastric LN, there were tumor regions exhibiting both adenocarcinoma and SCC histologies (Figure 2). A separate primary origin for the SCC was not established, despite evaluation for the usual sites of origin. The metastatic deposition of two primary malignancies into the same lymph node seems less likely to us than the hypothesis that this patient’s metastatic disease was manifested of the same primary tumor with significant clonal evolution and the development of ITH. To further support this premise, patients with MSI-H metastatic GC who have a robust response to pembrolizumab exhibited a reduction in the total size of mutant clones in post-treatment biopsy samples as determined by the ratio of nonsynonymous mutations to synonymous mutations (dN/dS ratio) [17]. In contrast, those with poor responses maintained a high dN/dS ratio, suggesting the evolutionary fitness of mutant subclones [17]. Kwon et al. observed baseline ITH in both responding and non-responding MSI-H patients, but heterogeneity was lost in responding patients, suggesting the maintenance of ITH may be intrinsically resistant to immunotherapy approaches. Interestingly, for our patient, the adenocarcinoma component of the LN biopsies exhibited the lowest number of mutations, presumably representative of some mixed response with the loss of this clone (Table 2). In contrast, the synchronous SCC component of the LN and earlier post-treatment timepoint peritoneal SCC maintained a high number of mutations, indicative of resistance and the overall progressive disease course.

Furthermore, Wolf et al. studied ITH within melanoma mouse models, demonstrating that the number of distinct clones comprising the tumor and genetic diversity play a role in tumor aggressiveness and its response to ICI [18]. We hypothesize that our patient had a significant amount of ITH, which may have led to immune evasion and a lack of response to ICI. In addition, high ITH can diminish clonal fraction sizes to an extent below a threshold sufficient to mount an immune response despite the presence of neoantigens [19]. We believe that despite being MSI-H in all the tumor samples and regardless of histology, the tumors were likely highly heterogenous, causing the dilution of the neo-antigens [18].

We highlight a clinical scenario that suggests the dedifferentiation of the primary tumor led to increased ITH for which we characterized clonality by whole-exome sequencing. We suspect that increased tumor heterogeneity led to the poor response to ICI, despite all tumor samples being MSI-H. We believe further work refining the characterization of intrapatient interlesional heterogeneity can help delineate which patients will derive the most benefit from ICI. Such efforts should be paired with immune gene expression profiling, which can characterize T-cell dysfunction and exclusion within the tumor immune microenvironment [20].

**Author Contributions:** Conceptualization, S.S. and J.C.; formal analysis, N.K., L.A., J.L., S.S. and J.C.; investigation, all authors; data curation, all authors; writing—original draft preparation, N.K. and J.C.; writing—review and editing, all authors; supervision, J.C.; funding acquisition, Y.W. and J.C.; All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was partially supported by the Stand Up To Gastric Cancer Interception Award (to Y.W. and J.C.).

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of City of Hope (protocol number 07047 and date of approval 24 December 2020) for studies involving humans.
Informed Consent Statement: Written informed consent was obtained from the patient for the collection, analysis, and publication of deidentified molecular and clinical data under an institutional-review-board-approved research protocol.

Conflicts of Interest: J.C. has received research funding (institutional) from Merck and Brooklyn Immunotherapeutics, has served in a consultant/advisory role for Lilly, Merck, AstraZeneca, Foundation Medicine, Daiichi Sankyo, Macroenerics, Amgen, Ono Pharmaceutical, Bristol-Myers Squibb, Astellas, Turning Point Therapeutics, Silverback Therapeutics, Novartis, Coherus Biosciences, Genoese, and Roche, and serves on the Speakers Bureau for Merck and Bristol-Myers Squibb. S.S. and J.L. are employees of Exact Sciences Corporation, a publicly traded company, and both hold company stocks. The remaining authors declare that they have no conflict of interest.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Weinberg, B.A.; Gowen, K.; Lee, T.K.; Ou, S.-H.I.; Bristow, R.; Krill, L.; Almira-Suarez, M.; Ali, S.M.; Miller, V.A.; Liu, S.V.; et al. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist 2017, 22, 152–157. [CrossRef] [PubMed]
3. Epstein, J.I.; Walsh, P.C.; Sanfilippo, F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am. J. Surg. Pathol. 1996, 20, 851–857. [CrossRef] [PubMed]
4. Divakar, V.; Muntal, T.; García-Hernandez, F.; Cortes, J.; Gonzalez, B.; Rubio, I.T. Changes in Breast Cancer Reports after Pathology Second Opinion. Breast J. 2014, 20, 295–301. [CrossRef] [PubMed]
5. Shipitsin, M.; Small, C.E.; Choudhury, S.; Giladi, E.; Friedlander, S.F.; Nardone, J.; Hussain, S.; Hurley, A.D.; Ernst, C.; Huang, Y.E.; et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer 2014, 111, 1201–1212. [CrossRef] [PubMed]
6. Johnson, D.B.; Dahlman, K.H.; Knol, J.; Gilbert, J.; Puzanov, I.; Means-Powell, J.; Ballo, J.M.; Lovly, C.M.; Murphy, B.A.; Goff, L.W.; et al. Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014, 19, 616–622. [CrossRef] [PubMed]
7. Pectasides, E.; Stachler, M.D.; Derks, S.; Liu, Y.; Maron, S.; Islam, M.; Alpert, L.; Ratnayake, J.; et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018, 8, 37–46. [CrossRef] [PubMed]
8. Hecht, J.R.; Bang, Y.J.; Qin, S.K.; Chung, H.C.; Xu, J.M.; Park, J.O.; Jeziorski, K.; Shparyk, Y.; Hoff, P.M.; Sobrero, A.; et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial. J. Clin. Oncol. 2016, 34, 443–451. [CrossRef] [PubMed]
9. Shah, M.A.; Bang, Y.J.; Lordick, F.; Alsina, M.; Chen, M.; Hack, S.P.; Bruey, J.M.; Smith, D.; McCaffery, I.; Shames, D.S.; et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin with or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGaStric Randomized Clinical Trial. JAMA Oncol. 2017, 3, 620–627. [CrossRef] [PubMed]
10. Catanacci, D.V.T.; Tebbutt, N.C.; Davidenko, I.; Murad, A.M.; Al-Batran, S.-E.; Ilson, D.H.; Tjulandin, S.; Gotovkin, E.; Karaszewska, B.; Bondarenko, I.; et al. Rilotumumab plus erupubicin, cisplatin, and capicitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal cancer (RIOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18, 1467–1482. [CrossRef]
11. Van Cutsem, E.; Bang, Y.J.; Mansoor, W.; Petty, R.D.; Chao, Y.; Cunningham, D.; Ferry, D.R.; Smith, N.R.; Frewer, P.; Ratnayake, J.; et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017, 28, 1316–1324. [CrossRef] [PubMed]
12. Lordick, F.; Kang, Y.-K.; Chung, H.; Salman, P.; Oh, S.C.; Bodoky, G.; Kurteva, G.; Volovat, C.; Moiseyenko, V.; Gorbunova, V.; et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14, 490–499. [CrossRef]
13. Waddell, T.; Chau, I.; Cunningham, D.; Gonzalez, D.; Okines, A.F.C.; Wotherspoon, A.; Saffery, C.; Middleton, G.; Wadley, J.; Ferry, D.; et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14, 481–489. [CrossRef]
14. Tabernero, J.; Hoff, P.M.; Shen, L.; Ohtsu, A.; Shah, M.A.; Cheng, K.; Song, C.; Wu, H.; Eng-Wong, J.; Kim, K.; et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018, 19, 1372–1384. [CrossRef]
15. White, T.; Szelinger, S.; LoBello, J.; King, A.; Aldrich, J.; Garinger, N.; Halbert, M.; Richholt, R.F.; Mastrian, S.D.; Babb, C.; et al. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®. *Oncotarget* 2021, 12, 726–739. [CrossRef] [PubMed]

16. Ostrovnaya, I.; Seshan, V.E.; Olshen, A.B.; Begg, C.B. Clonality: An R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. *Bioinformatics* 2011, 27, 1698–1699. [CrossRef]

17. Kwon, M.; An, M.; Klempner, S.J.; Lee, H.; Kim, K.-M.; Sa, J.K.; Cho, H.J.; Hong, J.Y.; Lee, T.; Min, Y.W.; et al. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. *Cancer Discov.* 2021, 11, 2168–2185. [CrossRef]

18. Wolf, Y.; Bartok, O.; Patkar, S.; Eli, G.B.; Cohen, S.; Litchfield, K.; Levy, R.; Jiménez-Sánchez, A.; Trabish, S.; Lee, J.S.; et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. *Cell* 2019, 179, 219–235.e21. [CrossRef] [PubMed]

19. Gejman, R.S.; Chang, A.Y.; Jones, H.F.; DiKun, K.; Hakimi, A.A.; Schietinger, A.; Scheinberg, D.A. Rejection of immunogenic tumor clones is limited by clonal fraction. *eLife* 2018, 7, e41090. [CrossRef] [PubMed]

20. Jiang, P.; Gu, S.; Pan, D.; Fu, J.; Sahu, A.; Hu, X.; Li, Z.; Traugh, N.; Bu, X.; Li, B.; et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat. Med.* 2018, 24, 1550–1558. [CrossRef] [PubMed]